Nyxxodine™ is our own alternative to other synthetically derived alkaloids - while chemically different, our trade-secret processes have placed heavy focus on making the Nyxxodine™ experience satisfying for regular consumers of other pouch-based products.

Nyxxodine™ contains no nicotine, is not a tobacco derivative, and is not a component of or part of a tobacco product. As such, it does not fall under the regulatory purview of the FDA’s Center for Tobacco Products.

Nyxxodine™ does not meet the definition of nicotine provided by the Family Smoking Prevention and Tobacco Control Act, is not a salt or complex of nicotine, and is not itself derived from tobacco or nicotine; accordingly, Nyxxodine™ is not subject to FDA tobacco requirements.

Nyxxodine™ is not intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.

Nyxxodine™ is intended only for experienced adult users of vapes and pouch-based products.

Nyxxodine™ is a trademarked ingredient synthesized under confidential licensure. This trade-secret process provides a nicotine-free, tobacco-free finished product from nicotine-free, tobacco-free starting ingredients.

Nyxxodine™ has been tested for chemical impurities and volatile organic compounds. The results indicate that Nyxxodine™ poses no additional risk when compared with other additives in conventional pouch-based products currently on the market.

Nyxxodine™ is not intended for use by pregnant or breastfeeding women.

Nyxxodine™ is structurally similar to nicotine, and it is expected that Nyxxodine™ will have a toxicity profile similar to nicotine.

• Nicotine is considered acutely toxic.
• Nicotine is not mutagenic nor carcinogenic.

Nicotine is considered to have potential adverse effects on reproduction. Women who are pregnant or breastfeeding should avoid both nicotine and Nyxxodine™.